Population Pharmacokinetic Modeling and Optimal Sampling Strategy for Bayesian Estimation of Amikacin Exposure in Critically Ill Septic Patients
Isabelle Delattre(Cliniques Universitaires Saint-Luc), Pierre Wallemacq(Cliniques Universitaires Saint-Luc), Joakim Nyberg(Uppsala University), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Fabio Taccone(Erasmus Hospital), Roger K. Verbeeck(UCLouvain), Frédérique Jacobs(Université Libre de Bruxelles), Flora T. Musuamba(Inserm)
Cited by 57
Related Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
|JAMA|2013|797
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
|The Lancet|2007|689
Deep Dermatophytosis and Inherited CARD9 Deficiency
|New England Journal of Medicine|2013|403